학술논문
Improving the in vivo QTc assay: Nonclinical concentration-QTc modeling for risk assessment.
Document Type
Academic Journal
Author
Wisialowski TA; Pfizer, Groton, CT, USA. Electronic address: todd.a.wisialowski@pfizer.com.; Ether N; Amgen Inc., Thousand Oaks, CA, USA.; Foley CM; AbbVie, North Chicago, IL, USA.; Kleiman R; Clario, Philadelphia, PA, USA.; Koshman Y; AbbVie, North Chicago, IL, USA.; Leishman D; Eli Lilly and Company, Indianapolis, IN, USA.; Martel E; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.; Nichols JV; Labcorp, Madison, WI, USA.; Popp J; Labcorp, Madison, WI, USA.; Rajamani S; Johnson & Johnson Innovative Medicine, CA, USA.; Riley S; Pfizer, Groton, CT, USA.; Rossman EI; GSK, Collegeville, PA, USA.; Vargas HM; Amgen Inc., Thousand Oaks, CA, USA.
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 9206091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-488X (Electronic) Linking ISSN: 10568719 NLM ISO Abbreviation: J Pharmacol Toxicol Methods Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: Declaration of competing interest None of the authors has any conflicts of interest, other than their employment in commercial biopharmaceutical companies or contract research organizations (CROs). No information is presented in this paper that advocates for or promotes commercial products from any of our organizations.